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Autologous haemopoietic stem cell transplantation (HSCT) represents a potential therapy for severe 
rheumatoid arthritis (RA). As a prelude to clinical trails, the safety and efficacy of haemopoietic stem 
cell (HSC) mobilisation required investigation as colony-stimulating factors (CSFs) have been reported 
to flare RA. A double-blind, randomised placebo-controlled dose escalation study was performed. Two 
cohorts of eight patients fulfilling strict eligibility criteria for severe active RA (age median 40 years, 
range 24-60 years; median disease duration 10.5 years, range 2-18 years) received filgrastim (r-Hu-
methionyl granulocyte(G)-(SF) at 5 and 10 µg/kg/day, randomised in a 5:3 ratio with placebo. Patients 
were unblinded on the fifth day of treatment and those randomised to filgrastim underwent cell 
harvesting (leukapheresis) daily until 2 ×  106/kg CD34+ cells (haemopoietic stem and progenitor cells) 
were obtained. Patients were assessed by clinical and laboratory parameters before, during and after 
filgrastim administration. RA flare was defined as an increase of 30% or more in two of the following 
parameters: tender joint count, swollen joint count or pain score. Efficacy was assessed by quantitation 
of CD34+ cells and CFU-GM. One patient in the 5µg/kg/day group and two patients in the 10 
µg/kg/day group fulfilled criteria for RA flare, although this did not preclude successful stem cell 
collection. Median changes in swollen and tender joint counts were not supportive of filgrastim 
consistently causing exacerbation of disease, but administration of filgrastim at 10 µg/kg/day was 
associated with rises in median C-reactive protein and median rheumatoid factor compared with 
placebo. Other adverse events were well recognised for filgrastim and included bone pain (80%) and 
increases in alkaline phosphatase (four-fold) and lactate dehydrogenase (two-fold). With respect to 
efficacy, filgrastim at 10 µg/kg/day was more efficient with all patients (n = 5) achieving target CD34+ 
cell counts with a single leukapheresis (median = 2.8, range = 2.3-4.8 × 106/kg, median CFU-GM = 
22.1, range = 4.2-102.9 × 104/kg), whereas 1-3 leukaphereses were necessary to achieve the target yield 
using 5 µg/kg/day. We conclude that filgrastim may be administered to patients with severe active RA 
for effective stem cell mobilisation. Flare of RA occurs in a minority of patients and is more likely with 
10 than 5 µg/kg/day. However, on balance, 10 µg/kg/day remains the dose of choice in view of more 
efficient CD34+ cell mobilisation. 
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Based on animal data and anecdotal case reports, haemopoietic stem cell transplantation (HSCT) 
has been proposed for the treatment of autoimmune diseases.1-9 Recent advances, including the use 
of cytokine mobilised peripheral blood stem cells, have resulted in major reductions in the 
mortality and morbidity of autologous transplantation for malignant diseases10-11 and it now seems 
reasonable to consider HSCT as an experimental treatment for severe autoimmune diseases. 
 
Rheumatoid arthritis (RA) is the most common systemic autoimmune disorder, affecting 1% of the 
population. RA incurs significant morbidity, with over 50% of individuals unable to work after 10 
years of the disease, and has been estimated to shorten life by 5-10 years. Although various 
treatments may suppress disease activity, they require chronic administration, and do not cure the 
disease or prevent irreversible end organ damage. The associated economic costs are considerable, 
both to the individual and to the community.12-13 Patients with severe refractory RA may be ideal 
candidates for experimental HSCT as, unlike other systemic autoimmune diseases, vital organ 
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function is usually uncompromised. In addition, RA is easily assessed by clinical and laboratory 
parameters.7 
 
As a preliminary to studies of high-dose therapy, the safety and efficacy of peripheral blood stem 
cell mobilisation in RA requires confirmation. Both granulocyte colony-stimulating factor (G-
CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF) have been shown to flare 
arthritis in mice.14-15 Anecdotal clinical reports have reported exacerbation of autoimmune disease 
following treatment with G-CSF and GM-CSF. These have largely been in the context of Felty's 
syndrome16-21 or drug-induced neutropenia.22-23 Other reports have suggested that colony-
stimulating factors may exacerbate vasculitis19,24,25 and psoriasis26 and precipitate bullous 
pyoderma gangrenosum27 and neutrophilic dermatosis.28 Potential causes for this effect may 
include leucocyte activation,29 secondary release of proinflammatory cytokines20 or possibly a 
direct effect on target tissues. However, there are many reports where CSFs have been used safely, 
for pro-longed periods, to treat neutropenia in rheumatoid arthritis.26,30-42 In some cases,43 it is 
unclear whether increased pain represents flare of disease or bone pain, which commonly 
accompanies CSF administration. 
 
In addition, the quality of the stem cell product must be established. Abnormalities in the 
haemopoietic and immune systems in patients with RA9,44 have the potential to influence numbers 
and repopulating ability of haemopoietic progenitor cells and the composition and function of 
other cellular effectors in the harvested product. Patients with severe RA may have been exposed 
to myelosuppressive anti-rheumatic drugs, in some cases for many years, potentially influencing 
the mobilisation product and function of the graft.44,45 
 
The primary objective of this study was to investigate the tolerability of granulocyte colony-
stimulating factor (r-Hu-methionyl G-CSF, filgrastim; Amgen, Thousand Oaks, CA, USA) in 
patients with severe active, but stable, rheumatoid arthritis using doses suitable for progenitor cell 
mobilisation. The secondary objectives were to determine whether laboratory parameters of 
inflammation, principally C-reactive protein, were affected by filgrastim and to investigate the 
yield of PBSC as measured by CD34+ and CFUGM assays. 
 
Patients and methods  
Study design 
 
This single centre study was approved by the Research Ethics Committee of St Vincent's Hospital 
and all patients gave informed consent. The design was a randomised, double blinded placebo-
controlled phase I dose escalation study with two cohorts of eight patients, with five randomised 
to filgrastim and three receiving placebo in each cohort. The first cohort received filgrastim at 5 
µg/kg/day. After acceptable tolerability (defined as less than two patients in the filgrastim group 
compared with the placebo group experiencing an increase of 30% or greater from treatment 
baseline in two of swollen joint count, tender joint count, and pain score, or more than two 
patients achieving a white cell count of >75 × 109/1, or other intolerable events related to 
filgrastim) was confirmed for the first cohort, the dose was escalated to 10 µg/kg/day for the 
second cohort. Patients received four daily doses of study drug or placebo in a double blind 
manner. On day 5, following assessment of clinical parameters, patients and assessors were 
unblinded and those receiving filgrastim underwent leukapheresis on a Cobe Spectra cell separator 
(Cobe, Lakewood, CO, USA) aiming to process 2.5 × blood volume. Leukapheresis was continued 
for a maximum of 3 consecutive days until the target CD34+ cell yield of 2 × 106/kg was achieved. 
Filgrastim was discontinued once the target yield was achieved or to a maximum of 6 days in 
total. Patients were reassessed at study completion on day 11, and also reviewed at a follow-up 
appointment 4-6 weeks following filgrastim administration. 
 
Patient selection 
Patients were enrolled 7-10 days before commencing filgrastim after satisfying the following 
eligibility criteria: age 18-65 years, a diagnosis of RA according to the criteria of the American 
College of Rheumatology (ACR)46 for 2-20 years, failure of at least two second-line anti-
rheumatic agents (i.e. anti-rheumatic drugs other than corticosteroids and non-steroidal anti-
inflammatory drugs, NSAIDs). In addition, they fulfilled criteria for active disease, i.e. had six or 
more swollen joints, six or more tender joints, plus at least two of the following three criteria: (1) 
nine or more joints, capable of response, tender on pressure or motion; (2) 1 h or more of 
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morning stiffness; (3) ESR of >28 mm/h. Patients had no other serious prior or intercurrent 
illness, including any major haematological disorder. Full blood count including differential and 
coagulation screen were within normal ranges or compatible with RA and/or its treatment (e.g. 
anaemia of chronic disorder, reactive neutrophilia and thrombocytosis, and lymphopenia due to 
corticosteroids were permitted). Biochemical screens showed plasma creatinine <0.15 mmol/l, 
liver enzymes <3 × the upper limit of normal and plasma bilirubin <30 mmol/l. Premenopausal 
women had to have a negative pregnancy test, not be breast feeding and use contraceptive 
precautions. Informed consent was signed by all patients. Exclusion criteria included concurrent 
enrolment on any other protocol using an investigational drug or haemopoietic growth factor 
within 4 weeks of study entry, any disorder that compromised ability to give informed consent, 
known sensitivity to E. coli-derived drug preparations and previous entry to the study. Each 
patient was given an identification number in order of enrolment, with 1001 to 1008 for cohort 1 
and 2001 to 2008 for cohort 2. 
 
Concomitant anti-rheumatic medications 
Patients were stabilised on corticosteroids and NSAIDs for at least 4 weeks prior to enrolment on 
the study and were continued at the same dose throughout the study. Minor fluctuations within the 
dose range of NSAIDs and paracetamol were permitted. Joint injections were not permitted within 
the 4-week ‘run in’ period or during the study. Additional paracetamol was permitted to manage 
side-effects associated with filgrastim (such as bone pain). Patients on methotrexate, azathioprine, 
gold, hydroxychloroquine, sulphasalazine, D-penicillamine or cyclophosphamide had received the 
drug at the same dose for 3 months prior to beginning the study. Myelosuppressive drugs were 
stopped 1 week prior to the first dose of the study drug and recommenced 8 days later. Hence, 
patients were stable on anti-rheumatic medication prior to administration of filgrastim. A 2-week 
cessation of myelosuppressive anti-rheumatic drugs, necessary to permit administration of filgras-
tim, was considered to be insufficient for their anti-rheumatic effect to be lost. 
 
Assessment of safety 
Prior to commencing treatment with the study drug, patients were assessed with baseline physical 
examination and measurement of swollen and tender joint counts (EULAR 28 joint count score), 
joint pain score on a 100 mm visual analogue scale (VAS), duration of morning stiffness 
(measured semi-quantitatively, 0 min, 0-30 min, 30-60 min, 1-2 h, 2-4 h, >4 h), adjectival patient 
and clinician global scales for disease (nil, mild, moderate, severe, very severe), vital signs, full 
blood count, plasma biochemistry, serum rheumatoid factor (RF), erythrocyte sedimentation rate 
(ESR), and C-reactive protein. All patients had a normal chest X-ray and ECG, with the exception 
of one patient in whom the ECG suggested ischaemic heart disease which had been excluded by 
cardiac angiography. Pre-treatment bone marrow aspirates in 14 out of 16 patients agreeing to the 
procedure confirmed normal appearances or appearances consistent with RA and/or its treatment 
in all patients. 
 
During the study, patients were assessed with daily full blood count on days 1-5 and on days 6 and 
7 where leukapheresis was performed. Plasma biochemistry, C-reactive protein, ESR and RF were 
repeated on the day after the final administration of the study drug. Patients completed a daily 
diary detailing pain score, morning stiffness, adjectival patient global scale and specific 
symptoms. Vital signs were recorded when patients attended clinic. On day 5, double-blind 
measurement of swollen joint count, tender joint count and adjectival clinician global scale were 
performed, after which patient and assessor were unblinded. 
 
The study was terminated at day 11 when all baseline assessments were repeated. Four to 6 weeks 
following study drug administration, a follow-up interview was con-ducted with repeat joint 
counts and blood tests. More than 95% of joint counts were performed by one assessor (AF), the 
remainder by a second assessor. Assessment before and after the blinded period was performed by 
the same assessor on all occasions. 
 
Assessment of efficacy 
CD34+ cell counts were assessed by flow cytometry as previously described.47 CFU-GM count 
was performed on thawed cells which had been frozen in 10% dimethyl sulphoxide using 14-day 
culture in methylcellulose media (Methocult GF H4434; Stem Cell Technologies, Vancouver, 
Canada) as previously described.48 
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Analysis of data 
Descriptive statistical methods (medians, ranges) were used to compare both filgrastim cohorts with the 
combined placebo group and to look for a dose escalation effect between the 5 and 10 µg/kg/day 
cohorts. To detect a flare in the RA of individual patients, we defined a flare as an increase from 
baseline of 30% or more of two of the following parameters; tender joint count, swollen joint count or 





Patient data are summarised in Table 1. All patients were Caucasian. One patient out of 10 
randomised to filgrastim required central venous access for leukapheresis in view of poor 
peripheral venous access. 
 
Safety data 
Descriptive data for changes in rheumatological variables are summarised in Tables 2-5. Three 
patients (patients 1003, 2003 and 2006) fulfilled criteria for flare, although this did not prevent 
successful stem cell collection. In one of these patients (2003) symptoms were sufficient to 
warrant an increase in dose of corticosteroids for 2 weeks (from 5 mg to 20 mg prednisolone daily). 
These clinical flares were associated with rises in C-reactive protein, ESR and rheumatoid factor 
(Table 4). The increased disease activity was also reflected by worsening in the semi-quantitative 
parameters shown in Table 3. 
 
Median values of swollen and tender joint counts and semi-quantitative assessment of morning 
stiffness and patient and clinician global assessments remained largely stable and were not 
supportive of filgrastim consistently causing exacerbation of disease (Tables 2, 3 and 4). Admin-
istration of filgrastim at 10 µg/kg/day was associated with a rise in median C-reactive protein 
level which corrected by day 11 and a progressive rise in rheumatoid factor at days 5 to 11 (Table 
5). It is difficult to comment on changes in ESR as there was a progressive rise in the placebo 
group. 
 
The median joint pain scores (by VAS) support a dose-dependent increase in pain during the 
blinded phase of the study, which improved after cessation of the filgrastim (Table 2). Here there 
may be some overlap with filgrastim induced bone pain, the most common adverse event occur-
ring in 8/10 filgrastim vs 0/6 placebo patients. Other adverse events were routine for filgrastim 
and included headache (5/10 filgrastim vs 2/6 placebo patients) and fatigue/tiredness (5/10 
filgrastim vs 2/6 placebo patients). There was an increase in median alkaline phosphatase from 
baseline on day 5 (3.5-3.9 × placebo) returning to 1.3-1.4 × placebo by day 11. Similarly, median 
LDH increased on day 5 (1.8-1.9 × placebo) and settled to 1.1-1.2 × placebo by day 11. The 
absence of significant change in disease activity of the placebo patients provided support that 
withdrawal of anti-rheumatic drugs for the short study period did not in itself exacerbate their RA. 
 
Efficacy data 
Filgrastim administration produced a significant rise in WCC (and neutrophil count) in both 
treatment groups, with a median peak of 42.7 × 109/1 (neutrophils 36.8 × 109/1) at day 6 in the 5 
µg/kg/day cohort and of 43.7 × 109/1 (neutrophils 38.8 × 109/1) at day 3 in the 10 µg/kg/day 
cohort. Yields of haemopoietic progenitors, measured principally by CD34+ cells/kg, are 
summarised in Table 6. Filgrastim at a dose of 10 µg/kg/day was more efficient in terms of 
mobilisation in that target CD34+ yields were achieved with one leukapheresis and total CFU-GM 
counts from this group were higher. 
 










This placebo controlled study is the first to investigate the safety and efficacy of filgrastim in 
patients with severe active RA for stem cell collection. In a minority of patients, filgrastim 
administration was associated with an early or late transient flare of RA, but this did not prevent 
successful harvesting. In only one patient was the flare significant enough to warrant an increase 
in the steroid dosage. Pro-genitor cell yields were satisfactory in all patients based on both CD34+ 
counts and CFU-GM assays, and fulfilled recently published criteria in the EBMT/EULAR 
consensus guidelines for autoimmune disease (i.e. CD34+ count >2 × 106/kg and CFU-GM >2 × 
I04/kg).6 In all patients receiving filgrastim at 10 ug/kg/day, the target threshold of 2 × 106/kg 
CD34+ cells was achieved with one leukapheresis. 







One other pilot study has recently addressed the safety of administering filgrastim to patients with 
RA 49 Five patients were given intramuscular or intra-articular methylprednisolone (median 80 
mg, range 40-120 mg) prior to administration of filgrastim at 5 µg/kg/day to protect against flare. 
Disease activity remained stable although the pre-administration of corticosteroids may have inhibited 
any pro-inflammatory effect of filgrastim. The patients did not undergo leukapheresis, but efficacy, 
quantitated indirectly using peripheral blood CD34+ count, was considered adequate. 
 
Our study differs in that it has shown that RA flare may be a complication of filgrastim administration 
for stem cell mobilisation. However, routine pre-administration of corticosteroids is unnecessary in the 
majority of patients. Use of anti-inflammatory agents (which in our study were kept stable for 1 month 
prior to and during the study period) could be individualised to minimise flare. Alternatively, the risks 
of flare could be discussed with the patient, who could then decide whether or not to receive intra-
articular or intramuscular steroid injections. 
 
Our results also show that the target thresholds can be achieved in one leukapheresis without the use of 
cytotoxic agents, such as cyclophosphamide, for priming. Although cyclophosphamide priming may 
increase the yield of PBSC, it has the potential to add morbidity and even mortality.11,50 In addition, a 
recent analysis suggests that the use of cyclophosphamide priming may contribute to an excess 
incidence of secondary myelodysplasia observed with peripheral blood stem cells compared with bone 
marrow in autologous transplantation.51 The above study is reassuring in that sufficient HSC may be 
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mobilised from most patients with RA with filgrastim alone. Avoidance of additional cytotoxic agents 
in mobilisation may be desirable in RA patients who even without the risks of autologous trans-
plantation are known to have a higher incidence of leukaemia from the disease and conventional 
treatments.52 
 
Further studies are necessary on stem cell mobilisation in patients with RA before large scale clinical 
trials of autologous HSCT can commence. Analysis of greater numbers of patients will define the risk 
of flare more accurately. Mobilised stem cells should be evaluated in short- and long-term in vitro 
culture to reassure that such harvests are able to reconstitute long-term haemopoiesis. The composition 
of the harvest should be determined and the functional properties of contaminating lymphocytes and 
other cellular effectors should be investigated. Such information may be valuable in planning graft 
manipulation strategies although at present it is unknown whether such processing will be clinically 
advantageous. Further investigation will naturally depend on the success of autografting in RA patients, 
although early results of unmanipulated autografting in sporadic cases53,54 and in our own clinical trial55 
appear promising. 
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